Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues

Journal of Endocrinological Investigation

Volumn 26, Issue 6, 2003, Pages 533-538

  Ronchi, Cristina L ^a   Orsi, E ^a   Giavoli, C ^a   Cappiello, V ^a   Epaminonda, P ^a   Beck Peccoz, P ^a   Arosio, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; Glucose metabolism; Insulin resistance; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; CARBOHYDRATE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HORMONE; INSULIN; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGE; AGED; ARTICLE; CARBOHYDRATE METABOLISM; COMPUTER PROGRAM; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PANCREAS SECRETION; QUANTITATIVE ANALYSIS;

EID: 0042525843     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345216     Document Type: Article

References (32)

1. Melmed S. Acromegaly. N. Engl. J. Med. 1990, 322: 966-977.
2. Foss M.C., Saad M.J.A., Paccola G.M.G.F., Paula F.J.A., Piccinato C.E., Moreira A.C. Peripheral glucose metabolism in acromegaly. J. Clin. Endocrinol. Metab. 1991, 72: 1048-1053.
3. Moller N, Schmitz O., Jorgensen J.O.L., et al. Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 1992, 74: 1012-1019.
4. Muggeo M., Robert S.B., Roth J., Kahn R. The insulin resistance of acromegaly: Evidence for two alterations in the insulin receptor on circulating monocytes. J. Clin. Endocrinol. Metab. 1979, 48: 17-25.
5. Hansen I., Tsalikian E., Beaufrere B., Gerich J., Haymond M., Rizza R. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action. Am. J. Physiol. 1986, 250: E269-E273.
6. Butler P., Kryshak E., Rizza R. Mechanism of growth hormone-induced postprandial carbohydrate intolerance in human. Am. J. Phisiol. 1991, 260: E513.
7. Randle P., Garland P., Hales C., Newsholme E. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1: 785-789.
8. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28: 412-419.
9. The Mexico City Diabetes Study. A prospective analysis of the HOMA model. Diabetes Care 1996, 19: 1138-1143.
10. Haffner S. M., Miettinen H., Stern M.P. The Homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20: 1087-1092.
11. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000, 85: 2402-2410.
12. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23: 57-63.
13. Ikeda Y., Suehiro T., Nakamura T., Kumon Y., Hashimoto K. Clinical significance of the insulin resistance index as assesssed by homeostasis model assessment. Endocr. J. 2001, 48: 81-86.
14. Bastard J.P., Robert J.J., Jardel C., Buckert E., Grimaldi A., Hainque I. Is quantitative insulin sensitivity check index, a fair insulin sensitivity in humans? Diabetes Metab. 2001, 27: 69-70.
15. De Fronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Phisiol. 1979, 237: 214-223.
16. McAuley K.A., Williams S.M., Mann J.I., et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001, 24: 460-464.
17. Hermans M.P., Levy J.C., Morris R.J., Turner R.C. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999, 42: 678-687.
18. Katsuki A., Sumida Y., Gabazza E.C., et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001, 24: 362-365.
19. Matsumoto K., Miyake S., Yano M., et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997, 20: 1562-568.
20. Lansang M.C., Williams G.H., Carroll J.S. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am. J. Hypertens. 2001, 14: 51-53.
21. Yildiz B.O., Gedik O. Insulin resistance in polycystic ovarian syndrome: Hyperandrogenemia versus normoandrogenemia Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 100: 62-66.
22. Bonora E., Formentini G., Calcaterra F., et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002, 25: 1135-1141.
23. Hanley A.J.G., Williams K., Stern M.P., Haffner S.M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care 2002, 25: 1177-1184.
24. Quon M.J. Editorial: Limitation of the fasting glucose to insulin ratio as an index of insulin sensitivity. J. Clin. Endocrinol. Metab. 2001, 86: 4615-4617.
25. Kasayama S., Otsuki M., Takagi M., et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. (Oxf.) 2000, 52: 549-555.
26. Giusti M., Gussoni G., Cuttica C.M., Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six months report on an Italian multicenter study. J. Clin. Endocrinol. Metab. 1996, 81: 2089-2097.
27. Ho K.K.Y., Jenkins A.B., Furler S.M., Borkman M., Chisholm D.J. Impact of octreotide, long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin. Endocrinol. (Oxf.) 1992, 36: 271-279.
28. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. Effects of treatment with octreotide in acromegalic patients - A multicenter Italian study. Eur. J. Endocrinol. 1995, 133: 922-928.
29. Colao A., Ferone D., Marzullo P., et al. Long-term effects of depot long acting somatostatin analogue octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab. 2001, 86: 2779-2796.
30. Luger A., Prager R., Gaube S., Graf H., Klauser R., Schertnthaner G. Decreased peripheral insulin sensitivity in acromegalic patients. Exp. Clin. Endocrinol. 1990, 95: 339-343.
31. Lamberts S.W., Uitterlinden P., Verschoor L., Van Dogen K.J., Del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N. Engl. J. Med. 1985, 313: 1576-1580.
32. Ronchi C., Epaminonda P., Cappiello V., Beck-Peccoz P., Arosio M. Effects of two different somatostatin analogues on glucose metabolism of GH levels in acromegaly. J. Endocrinol. Invest. 2002, 25: 502-507.